Bicycle Therapeutics plc (FRA:50BA)
Germany · Delayed Price · Currency is EUR 3.680
+0.080 (2.22%)
Last updated: Aug 26, 2026, 3:25 PM CET
Bicycle Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 61.21 | 72.59 | 35.28 | 26.98 | 14.46 | 11.7 | |
Revenue Growth | 217.44% | 105.77% | 30.76% | 86.52% | 23.65% | 12.58% |
Cost of Revenue | 189.06 | 229.08 | 164.86 | 147.65 | 81.61 | 44.88 |
Gross Profit | -127.85 | -156.5 | -129.59 | -120.68 | -67.15 | -33.18 |
Selling, General & Admin | 78.25 | 86.37 | 79.19 | 69.27 | 49.51 | 32.44 |
Operating Expenses | 78.25 | 86.37 | 79.19 | 69.27 | 49.51 | 32.44 |
Operating Income | -206.1 | -242.87 | -208.77 | -189.95 | -116.65 | -65.62 |
Interest Expense | -0.19 | -0.21 | -1.73 | -3.26 | -3.34 | -2.98 |
Interest & Investment Income | 21.81 | 28.46 | 34.28 | 14 | 5.76 | 0.12 |
EBT Excluding Unusual Items | -184.48 | -214.61 | -176.22 | -179.21 | -114.24 | -68.48 |
Other Unusual Items | -4.2 | -4.2 | 2.42 | - | - | - |
Pretax Income | -188.68 | -218.81 | -173.8 | -179.21 | -114.24 | -68.48 |
Income Tax Expense | 1.73 | 0.15 | -4.77 | 1.46 | -1.52 | -1.66 |
Net Income | -190.41 | -218.96 | -169.03 | -180.66 | -112.72 | -66.82 |
Net Income to Common | -190.41 | -218.96 | -169.03 | -180.66 | -112.72 | -66.82 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 70 | 69 | 58 | 36 | 30 | 25 |
Shares Outstanding (Diluted) | 70 | 69 | 58 | 36 | 30 | 25 |
Shares Change | 0.52% | 19.02% | 63.54% | 20.00% | 18.35% | 30.90% |
EPS (Basic) | -2.74 | -3.16 | -2.90 | -5.08 | -3.80 | -2.67 |
EPS (Diluted) | -2.74 | -3.16 | -2.90 | -5.08 | -3.80 | -2.67 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -208.28 | -252.03 | -165.96 | -63.56 | -105.1 | -16.82 |
Free Cash Flow Per Share | -3.00 | -3.64 | -2.85 | -1.79 | -3.54 | -0.67 |
Gross Margin | -208.89% | -215.60% | - | - | - | -283.69% |
Operating Margin | -336.74% | -334.59% | -591.84% | -704.13% | -806.56% | -560.98% |
Profit Margin | -311.11% | -301.66% | -479.18% | -669.72% | -779.35% | -571.25% |
Free Cash Flow Margin | -340.29% | -347.21% | -470.47% | -235.61% | -726.67% | -143.83% |
EBITDA | -200.81 | -236.44 | -201.6 | -183.4 | -112.96 | -64.21 |
D&A For EBITDA | 5.29 | 6.42 | 7.17 | 6.55 | 3.69 | 1.41 |
EBIT | -206.1 | -242.87 | -208.77 | -189.95 | -116.65 | -65.62 |